The FDA is proposing to remove semaglutide, tirzepatide, and liraglutide from the list of ingredients that outsourcing pharmacies can use to make bulk drug products. This change would prevent compounding pharmacies from manufacturing cheaper generic versions of these weight-loss and diabetes drugs.

• •FDA proposes excluding semaglutide, tirzepatide, liraglutide from 503B bulks list
• •Move would bar outsourcing facilities from compounding bulk versions of these drugs
• •Targets cheaper compounded alternatives to branded weight-loss and diabetes drugs

The FDA is proposing to remove semaglutide, tirzepatide, and liraglutide from the list of drugs that pharmacies can bulk-order for compounding (making custom doses). This would force patients to use brand-name versions of these weight-loss and diabetes drugs instead of cheaper pharmacy-made copies.

• •FDA proposes excluding semaglutide, tirzepatide, and liraglutide from 503B bulks list
• •Move would block pharmacies from bulk-ordering these APIs for compounding
• •Patients would be pushed toward brand-name versions

President Trump announced that the U.S. government will provide GLP-1 drugs (weight-loss and diabetes medications) to Medicare patients. The statement signals potential government coverage expansion for these expensive medications.

• •Trump said the U.S. will provide GLP-1 drugs to Medicare patients
• •Announcement signals potential federal coverage expansion for GLP-1s

The FDA plans to remove semaglutide, tirzepatide, and liraglutide from the list of drugs that large-scale pharmacies can legally make in bulk (called 503B compounding). This change would force patients to buy these weight-loss and diabetes drugs from manufacturers instead of cheaper pharmacy-made versions.

• •FDA plans to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list
• •Move would block large-scale pharmacy bulk compounding of these GLP-1s
• •Patients would need to source from manufacturers rather than compounded versions

The FDA is proposing to remove semaglutide, tirzepatide, and liraglutide from the list of drugs that pharmacies can use to make bulk copies under 503B rules (a program that lets facilities make custom medicines). This change would prevent large-scale compounding of these weight-loss and diabetes drugs, likely pushing patients toward branded versions.

• •FDA proposes excluding semaglutide, tirzepatide, liraglutide from 503B bulks list
• •Change would block large-scale compounding of these GLP-1 drugs
• •Patients would be pushed toward branded versions

The FDA is proposing to remove weight-loss drugs made by Novo Nordisk and Eli Lilly from a list of medicines that pharmacies can copy and make in bulk. This would be good for the companies because it would force more patients to buy their brand-name versions instead of cheaper pharmacy-made copies.

• •FDA proposes excluding Novo and Lilly weight-loss drugs from bulk compounding list
• •Move would restrict pharmacies from making bulk copies of the drugs
• •Patients would be pushed toward brand-name versions

Health Canada approved the first generic version of semaglutide (Ozempic), Novo Nordisk's popular diabetes and weight-loss drug. This means Canadian patients may soon have access to a cheaper alternative to the brand-name version.

• •Health Canada approved the first generic version of Ozempic (semaglutide).
• •Approval covers Novo Nordisk's diabetes and weight-loss drug.
• •Canadian patients may gain access to a cheaper alternative to the brand.

A drug made by Boehringer Ingelheim and Zealand Pharma helped people lose 16.6% of their body weight in a late-stage trial (a big test before the FDA decides whether to approve a medicine). This is positive news for the companies' weight-loss drug program.

• •Boehringer-Zealand drug delivered 16.6% weight loss in late-stage trial
• •Trial is Phase 3 (pre-FDA decision stage)

Boehringer Ingelheim's survodutide, a dual-action drug that targets two hormones (glucagon and GLP-1) to help with weight loss, showed people lost an average of 16.6% of their body weight in a late-stage trial. The drug also improved other measures of metabolic health in people with obesity or excess weight.

• •Survodutide delivered 16.6% weight loss in Phase 3 obesity trial
• •Drug is a glucagon/GLP-1 dual agonist from Boehringer Ingelheim, partnered with Zealand
• •Trial showed metabolic improvements in people with obesity or overweight

Eli Lilly's retatrutide, a next-generation weight-loss drug, has passed its first major late-stage trial (Phase 3 trial), which tests whether a drug actually works in patients. This is an important step toward getting the drug approved by regulators.

• •Retatrutide passed its first Phase 3 trial
• •Drug is positioned as Lilly's next-generation obesity therapy
• •Result advances retatrutide toward regulatory submission

Novo Nordisk is lowering the advertised U.S. prices for Ozempic (a diabetes drug) and Wegovy (a weight-loss drug) by as much as 50%. This is the company's move to make these expensive medications more affordable for patients and insurers.

• •Novo Nordisk to cut US list prices for Ozempic and Wegovy by up to 50%
• •Move targets affordability for patients and insurers

The FDA is proposing to stop pharmacies from making bulk copies of GLP-1 drugs (weight-loss and diabetes medications). This change could force more patients to buy expensive brand-name versions instead of cheaper compounded alternatives.

• •FDA proposing to end mass pharmacy compounding of GLP-1 drugs
• •Patients could be pushed toward brand-name versions
• •Compounded alternatives have been the cheaper option

The FDA is proposing new rules to limit pharmacies from making large quantities of generic copies of Novo Nordisk and Eli Lilly's weight-loss drugs. This could force patients to buy the more expensive brand-name versions instead of cheaper pharmacy-made alternatives.

• •FDA proposing rules to curb mass compounding of Novo and Lilly weight-loss drugs
• •Patients may be pushed toward more expensive brand-name versions
• •Targets pharmacy-made generic copies of GLP-1 weight-loss drugs

The FDA is proposing new rules to limit how much pharmacies can make generic copies of Novo Nordisk and Eli Lilly's weight-loss drugs. This could force more patients to buy the expensive brand-name versions instead of cheaper alternatives.

• •FDA proposing rules to limit pharmacy compounding of Novo and Lilly weight-loss drugs
• •Move could redirect patients to brand-name versions
• •Targets mass compounding of GLP-1 copies

The FDA is proposing to block pharmacies from making cheaper copies of GLP-1 weight-loss drugs, which would help Eli Lilly and Novo Nordisk sell more of their brand-name versions. This rule change could force patients to buy the expensive official medicines instead of lower-cost pharmacy-made alternatives.

• •FDA proposing to block pharmacies from compounding GLP-1 weight-loss drugs
• •Rule would favor branded versions from Eli Lilly and Novo Nordisk
• •Patients would lose access to lower-cost pharmacy-made alternatives

Boehringer Ingelheim announced that survodutide, a dual-action drug that works like both glucagon and GLP-1 (weight-loss hormones), helped people lose 16.6% of their body weight in a Phase III trial (a large late-stage test). The drug also improved other health markers related to metabolism in people with obesity or excess weight.

• •Survodutide hit 16.6% weight loss in Phase III obesity trial
• •Drug is a glucagon/GLP-1 dual agonist from Boehringer Ingelheim
• •Trial showed metabolic improvements in obesity/overweight patients

The FDA is taking steps to permanently ban pharmacies from making compounded versions of GLP-1 drugs (weight-loss and diabetes medications like semaglutide). This could force patients to buy more expensive brand-name versions instead of cheaper pharmacy-made copies.

• •FDA moving to permanently bar pharmacies from compounding GLP-1 drugs
• •Action targets compounded versions of semaglutide and related GLP-1s
• •Patients would be pushed toward more expensive brand-name products

The FDA is proposing to remove multiple GLP-1 drugs (a class of weight-loss and diabetes medicines) from a list of bulk ingredients that pharmacies are allowed to use to make cheaper compounded versions. This change could restrict pharmacies from making lower-cost copies and push patients toward buying more expensive brand-name versions.

• •FDA proposes excluding multiple GLP-1 RAs from the bulks list used for compounding
• •Move would restrict pharmacies from producing lower-cost compounded GLP-1 copies
• •Patients likely pushed toward higher-priced brand-name GLP-1 products

Apotex, a Canadian drugmaker, got approval from Health Canada to sell a generic copy of Ozempic (semaglutide), a popular weight-loss and diabetes medicine. This is the first generic version approved by Canada's health regulator.

• •Apotex received Health Canada approval for a generic equivalent of Ozempic (semaglutide)
• •First Canadian-based pharma company to win generic Ozempic approval in Canada

The FDA is proposing to remove weight-loss drugs from a list of medicines that pharmacies are allowed to make themselves (called compounding). This change could force patients to buy more expensive brand-name versions instead of cheaper pharmacy-made copies.

• •FDA proposing to exclude weight-loss drugs from pharmacy compounding list
• •Change would restrict pharmacies from making their own versions
• •Patients would face more expensive brand-name options

Canada approved a generic version of semaglutide (the active ingredient in Ozempic) made by Dr. Reddy's Laboratories. This generic copy is cheaper and could give more people access to the weight-loss and diabetes drug.

• •Canada approved Dr. Reddy's generic version of semaglutide
• •Semaglutide is the active ingredient in Novo Nordisk's Ozempic
• •Generic is cheaper and aims to broaden access for diabetes and weight loss

Dr. Reddy's Laboratories received approval from Health Canada to sell a generic version of semaglutide injection in Canada. This is the first generic copy of the popular weight-loss and diabetes drug to be approved there.

• •Dr. Reddy's received Health Canada approval for generic semaglutide injection
• •First generic semaglutide approved in Canada
• •Approval covers weight-loss and diabetes indications

Canada's health authority approved the first generic copy of semaglutide (Ozempic), the popular weight-loss and diabetes drug. This approval means cheaper versions of the medicine may become available as more companies compete to make GLP-1 drugs.

• •Canada approved the first generic version of semaglutide (Ozempic)
• •Approval opens the door to cheaper GLP-1 alternatives in Canada
• •Decision arrives amid rising competition in the GLP-1 class

• •Boehringer's dual-acting obesity shot met its endpoint in a Phase 3 trial

• •Boehringer's dual agonist hit 16.6% weight loss in phase 3
• •Phase 3 readout leaves key questions unanswered